cellvie
Cell & Gene Therapy · Health Care
$10.5Mtotal raised · 2 rounds on record
$5.5Mlatest round · Venture round · Feb 2023 · 3 yr ago
1backers · Taiho Ventures
10+team · employees, estimated range
Overview
At cellvie, we are pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at the cellular energy metabolism.
Key facts
These are the key facts about cellvie on Alion as of Nov 13, 2026. It has raised $10.5M in 2 funding rounds. The latest round is Venture - Series Unknown of $5.5M, announced in 2023.
- Employees
- 10+Alion company profile, an estimated range
- Total raised
- $10.5MSum of 2 equity rounds Alion knows
- Latest round
- Venture - Series Unknown · $5.5M · Feb 5, 2023Press report · wgno.com
Funding and backers
Total raised
$10.5M
2 rounds on record
Latest round
$5.5M
Venture round · Feb 2023 · 3 yr ago
Team
11-50
employees, estimated range
Backers
1
Taiho Ventures
The money's age
Long since its last round
45 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 5, 2023
Raised a round Venture round $5.5M
Jan 2021
Website went live first capture in the Wayback Machine
Jan 24, 2021
Raised a round Seed $5M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2023 | $5.5M | — | wgno.com |
| Seed | Jan 2021 | $5M | — | eurekalert.org |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with…
About Careers Contact Policies Scroll At Sylvatica, we're reimagining human health. We strive to transform organ transplantation, drug…
Pioneering Cell Therapies for the Central Nervous System. We are a Salt Lake City-based biotechnology company developing novel macrophage…
On this page Key figures Home > Who we are > Company Our mission is to turn scientific advances in gene therapy into novel treatments for…
Our Adenovo™ platform and 100-million-variant library move us from discovery to impact. With THEO-260 as our lead programme, our…
Avigen develops cellular avidity tools for immunotherapy and cell therapy R&D, helping identify potent and safe lead drug candidates faster.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Taiho VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
cellvie sichert sich 5 Millionen US-Dollar an frischem Kapital von bestehenden und neuen Investoren
Zürich - cellvie, ein Unternehmen, das Therapeutika auf der Basis von Mitochondrien entwickelt, gab den Abschluss einer Finanzierungsrunde in Höhe von 5 Millionen US-Dollar bekannt, an der sich sowohl
Read more
Report
How to cite this page
Alion, "cellvie: key facts", as of Nov 13, 2026. https://alion.io/company/cellvie
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0